<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>10(1)</volume><submitter>Fang W</submitter><funding>National Key R&amp;amp;D Program of China</funding><funding>National Key R&amp;D Program of China</funding><funding>Central Basic Scientific Research Fund for Colleges-Young Teacher Training Program of Sun Yat-sen University</funding><funding>Science and Technology Program of Guangdong</funding><funding>Chinese National Natural Science Foundation</funding><funding>Outstanding Young Talents Program of Sun Yat-sen University Cancer Center</funding><journal>Clinical and translational medicine</journal><pagination>331-336</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7240844</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Combinatorial assessment of ctDNA release and mutational burden predicts anti-PD(L)1 therapy outcome in nonsmall-cell lung cancer.</pubmed_title><pmcid>PMC7240844</pmcid><funding_grant_id>81602005</funding_grant_id><funding_grant_id>81772476</funding_grant_id><funding_grant_id>2017B020227001</funding_grant_id><funding_grant_id>17ykpy81</funding_grant_id><funding_grant_id>81872499</funding_grant_id><funding_grant_id>2016YFC0905503</funding_grant_id><funding_grant_id>16zxyc04</funding_grant_id><funding_grant_id>2016YFC0905500</funding_grant_id><pubmed_authors>Yin JC</pubmed_authors><pubmed_authors>Wang A</pubmed_authors><pubmed_authors>Ma Y</pubmed_authors><pubmed_authors>Wang F</pubmed_authors><pubmed_authors>Zhang L</pubmed_authors><pubmed_authors>Yang Y</pubmed_authors><pubmed_authors>Huang Y</pubmed_authors><pubmed_authors>Fang W</pubmed_authors><pubmed_authors>Bao H</pubmed_authors><pubmed_authors>Shao YW</pubmed_authors><pubmed_authors>Zhou H</pubmed_authors><pubmed_authors>Wu X</pubmed_authors><pubmed_authors>Hong S</pubmed_authors><pubmed_authors>Zhao H</pubmed_authors></additional><is_claimable>false</is_claimable><name>Combinatorial assessment of ctDNA release and mutational burden predicts anti-PD(L)1 therapy outcome in nonsmall-cell lung cancer.</name><description/><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Jan</publication><modification>2025-04-29T10:57:53.079Z</modification><creation>2025-04-06T19:46:42.886Z</creation></dates><accession>S-EPMC7240844</accession><cross_references><pubmed>32508057</pubmed><doi>10.1002/ctm2.8</doi></cross_references></HashMap>